Amgen, UCB’s Osteoporosis Candidate Shines in Phase 3 Trial

Amgen and UCB’s romosozumab met its primary endpoints in a Phase 3 study by reducing new vertebral fractures in postmenopausal women with osteoporosis through months 12 and 24.

The candidate also met a secondary endpoint of reducing the incidence of clinical fractures through 12 months, but missed its secondary endpoint of reducing the incidence of non-vertebral fractures through months 12 and 24.